NCT05651191View on ClinicalTrials.gov

To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 21, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2025

Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
DRUG

Human CD19 Targeted DASH CAR-T Cells Injection

Autologous genetically modified anti-CD19 CAR transduced T cells

Trial Locations (1)

330006

RECRUITING

The Second Affiliated Hospital of Nanchang University, Nanchang

Sponsors
All Listed Sponsors
collaborator

Second Affiliated Hospital of Nanchang University

OTHER

lead

Hrain Biotechnology Co., Ltd.

INDUSTRY